Praxis Precision Medicines, Inc.
PRAXDrugs in Pipeline
11
Phase 3 Programs
6
Upcoming Catalysts
4
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
PRAX Earnings Report
EPS Est: $-3.60 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How PRAX's past catalysts played out
40 mg/day vormatrogine for 12 weeks
Focal Epilepsy
PRAX-562
SCN2A Encephalopathy
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Focal Seizure
PRAX-114
Major Depressive Disorder
1mg elsunersen
Epileptic Encephalopathy
1.0mg/kg/day PRAX-562
Developmental and Epileptic Encephalopathy 1
PRAX-222 - Initial Dose
SCN2A-DEE
10 mg PRAX-114
Major Depressive Disorder
100 mg PRAX-944
Essential Tremor
30mg PRAX-628
Focal Onset Seizure
Part A: 20 and 40 mg PRAX-944
Essential Tremor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
40 mg/day vormatrogine for 12 weeks | Phase 3 | Focal Epilepsy | - | - |
PRAX-562 | Phase 3 | SCN2A Encephalopathy | - | - |
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Phase 3 | Focal Seizure | - | - |
PRAX-114 | Phase 3 | Major Depressive Disorder | - | - |
1mg elsunersen | Phase 3 | Epileptic Encephalopathy | - | - |
1.0mg/kg/day PRAX-562 | Phase 3 | Developmental and Epileptic Encephalopathy 1 | - | - |
PRAX-222 - Initial Dose | Phase 2 | SCN2A-DEE | - | - |
10 mg PRAX-114 | Phase 2 | Major Depressive Disorder | - | - |
100 mg PRAX-944 | Phase 2 | Essential Tremor | - | - |
30mg PRAX-628 | Phase 2 | Focal Onset Seizure | - | - |
Part A: 20 and 40 mg PRAX-944 | Phase 2 | Essential Tremor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Praxis Precision Medicines, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Praxis Precision Medicines, Inc.'s (PRAX) pipeline across Phase 3, Phase 2. Its lead program is 40 mg/day vormatrogine for 12 weeks (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Praxis Precision Medicines, Inc.'s next FDA catalyst?→
Praxis Precision Medicines, Inc.'s (PRAX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRAX biotech catalysts?→
Add PRAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Praxis Precision Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.